NCT06862063: NASCeAD

Next Generation Sequencing Analysis of Patients with Spontaneous Dissection of Cervical Arteries

Recruiting now NA Last updated 6 March 2025

What this trial tests

NA trial testing Genetic testing in Dissection Carotid Artery in 145 participants. Currently enrolling.

Timeline

1 December 2024

Primary endpoint
1 December 2030

1 December 2030

Quick facts

Lead sponsor	Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	145
Start date	1 December 2024
Primary completion	1 December 2030
Estimated completion	1 December 2030
Sites	1 location across Italy

Drugs / interventions tested

• Genetic testing

Conditions studied

• Dissection Carotid Artery — all drugs for Dissection Carotid Artery →
• Dissection Arterial — all drugs for Dissection Arterial →
• Dissecting Aneurysm — all drugs for Dissecting Aneurysm →

Sponsor

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Who can join

18 and older, any sex, with Dissection Carotid Artery or Dissection Arterial. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this observational study is to analyze the existence of a genetic predisposition in patients with spontaneous dissections of the cervical arteries (SCeAD).

The main questions it aims to answer are:

1. Which is the prevalence of pathogenic variants in genes coding for proteins involved in the structure or function of the connective tissue in adult patients with spontaneous dissections of the cervical arteries?
2. Which are the clinical characteristics of each single genetic variant identified?
3. Which are the clinical, radiological, laboratory variables associated with the finding of a pathogenic variant?
4. Are there differences between patients with SCeAD who have a pathogenic variant in a gene coding for proteins involved in the structure or function of the connective tissue and those who not?
5. There are differences in the risk of SCeAD recurrence between patients with SCeAD who have a pathogenic variant in a gene coding for proteins involved in the structure or function of the connective tissue and those who not?
6. There are differences in the risk of SCeAD recurrence based on the specific typology of genetic variant found?

Participants will be asked to undergo:

* a whole-CT total-body with contrast;
* a dysmorphological visit;
* a blood sampling for genetic testing;
* a neurological visit;
* Some follow-up visits.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.